Measuring dementia symptoms

.

Chapter 2 in Cost-Benefit Analysis and Dementia, 2022, pp 18-31 from Edward Elgar Publishing

Abstract: When a reduction in dementia symptoms is the centrepiece for evaluating dementia interventions, it is essential to have a quantitative measure of dementia symptoms. The contribution of this chapter is to describe and explain an instrument called the Clinical Dementia Rating (CDR) scale, in order that the impact of any dementia intervention can be detected. We also present a summary of the data source, provided by the National Alzheimer's Coordinating Center (NACC), which featured the CDR and all the other variables that were used to carry out the CBAs of the five new interventions. The CDR scale can be said to encapsulate the ten warning signs of dementia presented by the Alzheimer Association (AA). In the Analysis, we separate out abnormal signs of aging (indicative of dementia) from signs that are normal with aging. Why the CDR is more useful than other measures of dementia in the literature is explained.

Keywords: Development Studies; Economics and Finance; Environment; Sociology and Social Policy (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.elgaronline.com/view/9781839105753.00010.xml (application/pdf)
Our link check indicates that this URL is bad, the error code is: 503 Service Temporarily Unavailable

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:elg:eechap:19697_2

Ordering information: This item can be ordered from
http://www.e-elgar.com

Access Statistics for this chapter

More chapters in Chapters from Edward Elgar Publishing
Bibliographic data for series maintained by Darrel McCalla ().